Please login to the form below

Not currently logged in
Email:
Password:

British National Formulary moves to NICE

The National Institute for Health and Clinical Excellence is to take over responsibility for the British National Formulary from the Department of Health

The National Institute for Health and Clinical Excellence (NICE) is to take over responsibility for the British National Formulary (BNF) from the Department of Health (DH).

The move comes as a result of the Darzi review and the establishment of a new service, NHS Evidence, which aims to bring clinical information and evidence together, offering healthcare professionals and patients good quality information in one place.

As the independent organisation responsible for providing national guidance on public health, health technologies and clinical practice, NICE will take over responsibility for the BNF.

Dr Gillian Leng, interim chief operating officer for NHS Evidence and NICE deputy chief executive, said: "We are delighted that the BNF will become a key part of NHS Evidence at NICE. NICE is looking forward to working in partnership with the BNF to ensure that it continues to provide high quality and clinically relevant advice."

The BNF provides independent, authoritative information about the use of medicines and is a key reference source for doctors, pharmacists and other healthcare professionals.
 

16th December 2008

From: Healthcare

Share

Subscribe to our email news alerts

PMHub

Add my company
Evoke Mind+Matter

We are Evoke Mind ‘PLUS’ Matter. The ‘plus’ is important to us because we are all about offering more for...

Latest intelligence

New Playbook Alert: Virtual Patient Engagement
...
Millennials: the wellness generation
Looking at the results from a global healthcare research study focusing on the patients of the future...
The problem with clinical trials (and how virtual insight-gathering can help)
While still the gold standard of research, clinical trials are often riddled with issues that limit their applicability to broader populations or delay market access....